Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development (GEN3G)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01623934|
Recruitment Status : Active, not recruiting
First Posted : June 20, 2012
Last Update Posted : May 4, 2017
This study includes 2 phases. During phase 1, pregnant women are followed over the course of pregnancy. The phase 2 is a follow-up of the mother-child dyad at 3 and 5 year after delivery.
The purpose of this phase 1 is to :
- assess the contribution and interactions of adipokines in the development of insulin resistance during pregnancy and gestational diabetes;
- assess levels of maternal adipokines as determinants of development and fetal growth;
- determine the genetic variations that influence levels of adipokines and glucose regulation during pregnancy and in newborns.
The purpose of this phase 2 is to:
- identify DNA methylation variations at birth that are predictive of childhood overweight/obesity.
- identify maternal characteristics associated with DNA methylation variations predictive of childhood overweight/obesity.
- establish whether the loci predictive of childhood overweight/obesity at birth are still differentially methylated at 5 years of age (samples collected at 5 years of age).
- identify DNA methylation variations at birth that are predictive of childhood neurodevelopment problems at 3 and 5 years of age.
|Condition or disease|
|Gestational Diabetes Insulin Resistance|
|Study Type :||Observational|
|Actual Enrollment :||1086 participants|
|Official Title:||Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development|
|Study Start Date :||January 2010|
|Estimated Primary Completion Date :||May 2019|
|Estimated Study Completion Date :||May 2019|
|Phase 1: Pregnant women|
|Phase 2: Mother-offspring dyad|
- Diagnosis of gestational diabetes mellitus [ Time Frame: 24-28 weeks of gestation ]75g oral glucose tolerance test
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01623934
|Centre de recherche Étienne-Le Bel, Centre hospitalier universitaire de Sherbrooke|
|Sherbrooke, Quebec, Canada, J1H5N4|
|Principal Investigator:||Marie-France Hivert, MD, MSc||Université de Sherbrooke|